BALTIMORE, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft platform.
Anti-angiogenic compounds are designed to work by blocking the tumor’s blood supply. There are multiple approved and experimental anti-angiogenic compounds for colorectal, breast, and lung cancer. Teva is developing agents in this area to help treat various forms of cancer.
Under the terms of the agreement, Champions will use its Champions Tumorgraft platform to test the effectiveness of Teva’s compound in various cancer indications to assist in further clinical development. “We are very excited to work with Teva on this program. The use of our highly-predictive Champions Tumorgraft platform will provide Teva with the data necessary for critical drug development decisions and help focus and accelerate the development program for this compound,” said Elizabeth Bruckheimer, Ph.D., Vice President of Scientific Operations, Champions Biotechnology, Inc.
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced translational platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company’s Technology Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Champions Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.
www.championsbiotechnology.com
SOURCE Champions Biotechnology, Inc.
